SenesTech Announces CEO Transition Plan
SenesTech (NASDAQ: SNES) announced that President and CEO Joel Fruendt plans to retire and will remain in his role until a successor is found or June 30, 2026.
Rhea-AI Summary
SenesTech (NASDAQ: SNES) announced that President and CEO Joel Fruendt plans to retire and will remain in his role until a successor is found or June 30, 2026. The Board will launch a formal search and has appointed Dr. Jamie Bechtel as Interim Executive Chair to support strategic alignment and continuity during the transition.
The company said interim COO Michael Edell and CFO Tom Chesterman will continue day-to-day operations while an executive search firm assists the Board.
Positive
- Successful product launch of Evolve across retail and professional channels
- Planned transition with CEO remaining through search or until June 30, 2026
- Interim Executive Chair appointed to support strategic alignment and continuity
Negative
- Leadership change creates near-term uncertainty for executive direction
- No successor named yet; Board must complete an external executive search
Details
News Market Reaction – SNES
In the Jan 29 session, SNES declined 1.05%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- CEO retirement outside date
- June 30, 2026
- Latest date Joel Fruendt will remain President and CEO
- Interim Executive Chair pay
- $247,500 per year
- Compensation for Jamie Bechtel as Interim Executive Chair
- ATM newly registered
- $7,580,675 of shares
- Additional common stock registered under at-the-market program
- ATM shares already sold
- $3,048,894.72
- Aggregate common stock sold via at-the-market program before Sept 24, 2025
- Q3 2025 revenue
- $690,000
- Record quarterly revenue reported in Q3 2025
- Revenue growth rate
- 43%
- Q3 2025 revenue growth vs Q3 2024
- Cash & investments
- $10.2M
- Cash, cash equivalents and short-term investments as of Sept 30, 2025
- Current share price
- $1.92
- Stock price before CEO transition announcement
Historical Context
-
Belize Raptor Center named distributor for Evolve Rat Birth Control.
-
Q3 2025 record revenue, higher margins, narrowed net loss and EBITDA loss.
-
Evolve Rat Birth Control launched on Lowes.com, expanding online reach.
-
Announcement of date and webcast details for Q3 2025 results call.
-
Swampscott pilot of Evolve Rat Birth Control at firehouse and school.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Board To Initiate Search For New Leadership As Current CEO Plans Retirement
Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition
Mr. Fruendt joined SenesTech in 2022 and has overseen the Company's development and launch of its revolutionary new product, Evolve®, across multiple retail and professional channels.
In addition, to further support this transition, the Board has appointed Dr. Jamie Bechtel, current Chair of the Board, to the newly created role of Interim Executive Chair. In this role, Dr. Bechtel will partner with management to support strategic alignment, execution discipline, and clear communication between the Board and the leadership team. This position is intended to reinforce management accountability and ensure continuity – without assuming day-to-day operational responsibilities.
"Joel has played a pivotal role in positioning SenesTech for future growth, particularly through the successful launch of Evolve®, and a renewed focus on operational execution," said Dr. Jamie Bechtel, Chair of the Board. "We are grateful for his leadership and his dedication to the Company's mission."
"It has been a privilege to lead the SenesTech team through this important chapter in the Company's growth," said Fruendt. "We've made strong progress expanding access to our effective and sustainable fertility control solutions, and I'm proud of what we've accomplished together. As I plan for my retirement, I remain committed to supporting a smooth and thoughtful transition."
"The Board has full confidence in a smooth and orderly transition, supported by our strong management team. Interim COO Michael Edell and CFO Tom Chesterman will continue leading the day-to-day execution of our plans," added Dr. Bechtel. "As Interim Executive Chair, I will be supporting the management team during this transitional period by helping ensure strategic alignment, execution discipline, and clear communication between the Board and the organization."
The Board will engage an executive search firm to assist in identifying a qualified successor to lead SenesTech in its next chapter.
About SenesTech, Inc.
SenesTech is committed to creating healthier environments by humanely managing animal pest populations through fertility control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are humane, effective, and sustainable.
For more information, visit https://senestech.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. These include, but are not limited to, the successful commercialization of our products, regulatory approvals, and market acceptance. SenesTech does not undertake any obligation to update forward-looking statements except as required by law.
Company Contact:
Tom Chesterman, CFO
(928) 233-7533
View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-ceo-transition-plan-302673042.html
SOURCE SenesTech, Inc.